ProxsysRx’s process for recovering lost 340B savings and revenue
As we’ve noted in multiple earlier blog posts, 340B ESP is nothing short of a blatant, lawless tactic used by scores of drug manufacturers to disallow the discounts they are legally obligated to offer eligible entities. At the same time, a number of additional manufacturers are placing — separate from 340B ESP — similarly-unlawful, and unnecessary, reporting burdens on hospitals submitting claims for 340B savings.
A brief history of 340B-related manufacturer restrictions.
The drug manufacturing industry first implemented 340B restrictions with the June, 2020 launch of 340B ESP — an online portal operated by Second Sight Solutions, which is a privately owned corporation created and run by a man with a long history of drug-industry advocacy. According to HRSA, the site has no legal right to impose its restrictions on covered entities. Read More >>
ProxsysRx is here to help, if you have questions.
There are so many ways to optimize your health system’s 340B drug program savings and benefits, while minimizing the likelihood of noncompliance. For more information, contact Howard Hall.
C: 205.588.0946 | howard.hall@proxsysrx.com
ProxsysRx offers hospital systems proven solutions for optimizing pharmacy services’ positive impact on the continuum of care; solutions ranging from management of their 340B prescription-savings programs, Retail and Specialty Pharmacy operations, to Prescription Benefits program management, and patient financial assistance.
This post is related to:
340B Solutions, 340B Management Systems
